Context Therapeutics Ownership 2024 | Who Owns Context Therapeutics Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

24.65%

Insider Ownership

2.78%

Retail Ownership

72.57%

Institutional Holders

25.00

Context Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
OPALEYE MANAGEMENT INC.6.94%0.35%1,108,357133,35713.68%1,529,533Mar 31, 2024
ALLY BRIDGE GROUP (NY) LLC4.55%0.56%725,951--1,001,812Mar 31, 2024
VANGUARD GROUP INC3.75%-598,3032,2910.38%825,658Mar 31, 2024
AFFINITY ASSET ADVISORS, LLC2.06%0.06%328,817--453,767Mar 31, 2024
UBS OCONNOR LLC1.86%0.03%296,675--409,412Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC1.29%0.06%205,934205,934100.00%284,189Mar 31, 2024
HIGHTOWER ADVISORS, LLC0.79%0.00%125,852--174,000Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.66%0.00%105,809--146,016Mar 31, 2024
MILL CREEK CAPITAL ADVISORS, LLC0.66%0.00%104,631--144,391Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.63%-101,0723,8323.94%139,547Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.25%0.00%39,9007,70023.91%55,000Mar 31, 2024
NORTHERN TRUST CORP0.23%-37,219--51,362Mar 31, 2024
CLEAR HARBOR ASSET MANAGEMENT, LLC0.23%0.00%36,000--49,680Mar 31, 2024
STATE STREET CORP0.21%-32,907--45,412Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.14%-22,38922,389100.00%30,897Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT0.13%0.00%20,000--27,600Mar 31, 2024
CITADEL ADVISORS LLC0.09%-15,041-839-5.28%20,757Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.0.07%0.00%11,45311,453100.00%15,805Mar 31, 2024
XTX TOPCO LTD0.06%0.00%10,26110,261100.00%14,160Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.04%0.00%6,357-298-4.48%8,773Mar 31, 2024

Context Therapeutics's largest institutional shareholder is OPALEYE MANAGEMENT INC., holding 6.94% of the company's total share outstanding, currently valued at $1.53M. The top 10 institutional shareholders own together 23.18% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ALLY BRIDGE GROUP (NY) LLC4.55%0.56%725,951--1,001,812Mar 31, 2024
OPALEYE MANAGEMENT INC.6.94%0.35%1,108,357133,35713.68%1,529,533Mar 31, 2024
ADAR1 CAPITAL MANAGEMENT, LLC1.29%0.06%205,934205,934100.00%284,189Mar 31, 2024
AFFINITY ASSET ADVISORS, LLC2.06%0.06%328,817--453,767Mar 31, 2024
UBS OCONNOR LLC1.86%0.03%296,675--409,412Mar 31, 2024
CLEAR HARBOR ASSET MANAGEMENT, LLC0.23%0.00%36,000--49,680Mar 31, 2024
MILL CREEK CAPITAL ADVISORS, LLC0.66%0.00%104,631--144,391Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT0.13%0.00%20,000--27,600Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.66%0.00%105,809--146,016Mar 31, 2024
XTX TOPCO LTD0.06%0.00%10,26110,261100.00%14,160Mar 31, 2024
HIGHTOWER ADVISORS, LLC0.79%0.00%125,852--174,000Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.04%0.00%6,357-298-4.48%8,773Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.0.07%0.00%11,45311,453100.00%15,805Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.25%0.00%39,9007,70023.91%55,000Mar 31, 2024
RETIREMENT GROUP, LLC0.00%0.00%155--214Mar 31, 2024
VANGUARD GROUP INC3.75%-598,3032,2910.38%825,658Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.63%-101,0723,8323.94%139,547Mar 31, 2024
NORTHERN TRUST CORP0.23%-37,219--51,362Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.14%-22,38922,389100.00%30,897Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.0.01%-1,500--2,070,000Mar 31, 2024

The largest Context Therapeutics shareholder by % of total assets is ALLY BRIDGE GROUP (NY) LLC. The company owns 725.95K shares of Context Therapeutics (CNTX), representing 0.56% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ADAR1 CAPITAL MANAGEMENT, LLC1.29%0.06%205,934205,934100.00%284,189Mar 31, 2024
OPALEYE MANAGEMENT INC.6.94%0.35%1,108,357133,35713.68%1,529,533Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.14%-22,38922,389100.00%30,897Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.0.07%0.00%11,45311,453100.00%15,805Mar 31, 2024
XTX TOPCO LTD0.06%0.00%10,26110,261100.00%14,160Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.25%0.00%39,9007,70023.91%55,000Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC0.63%-101,0723,8323.94%139,547Mar 31, 2024
VANGUARD GROUP INC3.75%-598,3032,2910.38%825,658Mar 31, 2024
0.00%-400400100.00%552Mar 31, 2024
JPMORGAN CHASE & CO0.00%-331043.48%46Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-11621.75%160,000Mar 31, 2024
STATE STREET CORP0.21%-32,907--45,412Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.0.01%-1,500--2,070,000Mar 31, 2024
NORTHERN TRUST CORP0.23%-37,219--51,362Mar 31, 2024
RETIREMENT GROUP, LLC0.00%0.00%155--214Mar 31, 2024
HIGHTOWER ADVISORS, LLC0.79%0.00%125,852--174,000Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.66%0.00%105,809--146,016Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT0.13%0.00%20,000--27,600Mar 31, 2024
MILL CREEK CAPITAL ADVISORS, LLC0.66%0.00%104,631--144,391Mar 31, 2024
CLEAR HARBOR ASSET MANAGEMENT, LLC0.23%0.00%36,000--49,680Mar 31, 2024

As of Mar 31 2024, Context Therapeutics's largest institutional buyer is ADAR1 CAPITAL MANAGEMENT, LLC. The company purchased 205.93K stocks of CNTX, valued at $284.19K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ASPIRE WEALTH MANAGEMENT CORP----10,000-100.00%-Mar 31, 2024
UBS GROUP AG----9,490-100.00%-Mar 31, 2024
CITADEL ADVISORS LLC0.09%-15,041-839-5.28%20,757Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)0.04%0.00%6,357-298-4.48%8,773Mar 31, 2024
BANK OF AMERICA CORP /DE/----109-100.00%-Mar 31, 2024
ALLY BRIDGE GROUP (NY) LLC4.55%0.56%725,951--1,001,812Mar 31, 2024
AFFINITY ASSET ADVISORS, LLC2.06%0.06%328,817--453,767Mar 31, 2024
UBS OCONNOR LLC1.86%0.03%296,675--409,412Mar 31, 2024
CLEAR HARBOR ASSET MANAGEMENT, LLC0.23%0.00%36,000--49,680Mar 31, 2024
MILL CREEK CAPITAL ADVISORS, LLC0.66%0.00%104,631--144,391Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT0.13%0.00%20,000--27,600Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.66%0.00%105,809--146,016Mar 31, 2024
HIGHTOWER ADVISORS, LLC0.79%0.00%125,852--174,000Mar 31, 2024
RETIREMENT GROUP, LLC0.00%0.00%155--214Mar 31, 2024
NORTHERN TRUST CORP0.23%-37,219--51,362Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.0.01%-1,500--2,070,000Mar 31, 2024
STATE STREET CORP0.21%-32,907--45,412Mar 31, 2024
WELLS FARGO & COMPANY/MN0.00%-11621.75%160,000Mar 31, 2024
JPMORGAN CHASE & CO0.00%-331043.48%46Mar 31, 2024
0.00%-400400100.00%552Mar 31, 2024

As of Mar 31 2024, Context Therapeutics's biggest institutional seller is ASPIRE WEALTH MANAGEMENT CORP. The company sold -10.00K shares of CNTX, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ADAR1 CAPITAL MANAGEMENT, LLC1.29%0.06%205,934205,934100.00%284,189Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.14%-22,38922,389100.00%30,897Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.0.07%0.00%11,45311,453100.00%15,805Mar 31, 2024
0.00%-400400100.00%552Mar 31, 2024

Context Therapeutics's largest new institutional shareholder by number of shares is ADAR1 CAPITAL MANAGEMENT, LLC, purchased 205.93K shares, valued at $284.19K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ASPIRE WEALTH MANAGEMENT CORP----10,000-100.00%-Mar 31, 2024
UBS GROUP AG----9,490-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----109-100.00%-Mar 31, 2024

Context Therapeutics's largest sold out institutional shareholder by shares sold is ASPIRE WEALTH MANAGEMENT CORP, sold -10.00K shares, valued at -, as of undefined.

Context Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
BRIDGEWAY FUNDS INC0.04%105,809--Dec 29, 2023
VANGUARD INDEX FUNDS0.00%618,62425,1334.23%Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%95,5953,2723.54%Feb 29, 2024
NATIONWIDE MUTUAL FUNDS0.00%9,400--Jan 31, 2024
iSHARES TRUST0.00%15,945--Feb 29, 2024
EQ ADVISORS TRUST0.00%1,016--Dec 31, 2023

Context Therapeutics's largest mutual fund holder by % of total assets is "BRIDGEWAY FUNDS INC", owning 105.81K shares, compromising 0.04% of its total assets.

Context Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 24258.70%
31 Dec, 23234.55%
30 Sep, 23224.76%
30 Jun, 232110.53%
31 Mar, 2319-13.64%
31 Dec, 222210.00%
30 Sep, 222017.65%
30 Jun, 221741.67%
31 Mar, 2212-25.00%
31 Dec, 2116-

As of 31 Mar 24, 25 institutions are holding Context Therapeutics's shares, representing an increase of 8.70% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 243,935,13210.59%
31 Dec, 233,558,23938.01%
30 Sep, 232,578,25615.16%
30 Jun, 232,238,76677.40%
31 Mar, 231,262,007-67.50%
31 Dec, 223,882,945-5.68%
30 Sep, 224,116,70213.04%
30 Jun, 223,641,96225.39%
31 Mar, 222,904,420-18.17%
31 Dec, 213,549,370-

Context Therapeutics (CNTX) has 3.94M shares outstanding as of 31 Mar 24, up 10.59% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2424.65%4.96%
31 Dec, 2322.29%8.55%
30 Sep, 2316.15%8.21%
30 Jun, 2314.02%22.44%
31 Mar, 237.90%1.34%
31 Dec, 2224.32%3.66%
30 Sep, 2225.78%4.96%
30 Jun, 2222.81%6.89%
31 Mar, 2218.19%1.51%
31 Dec, 2134.76%-

As of 31 Mar 24, Context Therapeutics is held by 24.65% institutional shareholders, representing a 4.96% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 241122.22%
31 Dec, 239-10.00%
30 Sep, 2310-
30 Jun, 231066.67%
31 Mar, 236-50.00%
31 Dec, 2212-7.69%
30 Sep, 22138.33%
30 Jun, 221250.00%
31 Mar, 228-50.00%
31 Dec, 2116-

11 institutional shareholders have increased their position in CNTX stock as of 31 Mar 24 compared to 9 in the previous quarter (a 22.22% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 242100.00%
31 Dec, 231-
30 Sep, 231-50.00%
30 Jun, 232-66.67%
31 Mar, 236-
31 Dec, 226-
30 Sep, 22--100.00%
30 Jun, 221-50.00%
31 Mar, 222-
31 Dec, 21--

2 institutional shareholders have reduced their position in CNTX stock as of 31 Mar 24 compared to 1 in the previous quarter (a 100.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 24258.70%3,935,13210.59%24.65%4.96%1122.22%2100.00%
31 Dec, 23234.55%3,558,23938.01%22.29%8.55%9-10.00%1-
30 Sep, 23224.76%2,578,25615.16%16.15%8.21%10-1-50.00%
30 Jun, 232110.53%2,238,76677.40%14.02%22.44%1066.67%2-66.67%
31 Mar, 2319-13.64%1,262,007-67.50%7.90%1.34%6-50.00%6-
31 Dec, 222210.00%3,882,945-5.68%24.32%3.66%12-7.69%6-
30 Sep, 222017.65%4,116,70213.04%25.78%4.96%138.33%--100.00%
30 Jun, 221741.67%3,641,96225.39%22.81%6.89%1250.00%1-50.00%
31 Mar, 2212-25.00%2,904,420-18.17%18.19%1.51%8-50.00%2-
31 Dec, 2116-3,549,370-34.76%-16---

Context Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Feb 21, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,823$0.84$4.90K159,701
Feb 13, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,606$0.87$4.90K153,878
Feb 06, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,040$0.97$4.90K148,272
Jan 30, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy7,027$0.70$4.90K143,232
Jan 23, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy6,839$0.72$4.90K136,205
Jan 18, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy6,783$0.74$5.00K129,366
Dec 19, 2022Minai-Azary Jennifer Lynnofficer Chief Financial OfficerP-PurchaseBuy25,000$0.74$18.50K40,000
Dec 19, 2022Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy20,000$0.74$14.80K122,583
Dec 12, 2022Levit Alex C.officer Chief Legal Officer, Corp. SecP-PurchaseBuy6,000$0.85$5.09K9,000
Aug 22, 2022Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy13,000$1.85$24.06K102,583

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Feb 21, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,823$0.84$4.90K159,701
Feb 13, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,606$0.87$4.90K153,878
Feb 06, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,040$0.97$4.90K148,272
Jan 30, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy7,027$0.70$4.90K143,232
Jan 23, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy6,839$0.72$4.90K136,205
Jan 18, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy6,783$0.74$5.00K129,366
Dec 19, 2022Minai-Azary Jennifer Lynnofficer Chief Financial OfficerP-PurchaseBuy25,000$0.74$18.50K40,000
Dec 19, 2022Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy20,000$0.74$14.80K122,583
Dec 12, 2022Levit Alex C.officer Chief Legal Officer, Corp. SecP-PurchaseBuy6,000$0.85$5.09K9,000
Aug 22, 2022Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy13,000$1.85$24.06K102,583

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Mar 22, 2024Minai-Azary Jennifer Lynnofficer Chief Financial OfficerA-AwardBuy160,115$1.07$171.32K160,115
Mar 22, 2024Levit Alex C.officer Chief Legal Officer, Corp. SecA-AwardBuy153,515$1.07$164.26K153,515
Mar 22, 2024Lehr Martin A.director, officer Chief Executive OfficerA-AwardBuy291,402$1.07$311.80K291,402
May 31, 2023Kantoff Philip W.director-A-AwardBuy25,000$0.87$21.75K25,000
May 31, 2023West Lindadirector-A-AwardBuy25,000$0.87$21.75K25,000
May 31, 2023Stacey Jennifer Evansdirector-A-AwardBuy25,000$0.87$21.75K25,000
May 31, 2023BERMAN RICHARD Jdirector-A-AwardBuy50,000$0.87$43.50K50,000
Feb 21, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,823$0.84$4.90K159,701
Feb 14, 2023Levit Alex C.officer Chief Legal Officer, Corp. SecA-AwardBuy151,505$0.84$127.37K151,505
Feb 14, 2023Lehr Martin A.director, officer Chief Executive OfficerA-AwardBuy287,544$0.84$241.74K287,544
Feb 14, 2023Minai-Azary Jennifer Lynnofficer Chief Financial OfficerA-AwardBuy158,001$0.84$132.83K158,001
Feb 13, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,606$0.87$4.90K153,878
Feb 06, 2023Lehr Martin A.director, officer Chief Executive OfficerP-PurchaseBuy5,040$0.97$4.90K148,272
Jan 30, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy7,027$0.70$4.90K143,232
Jan 23, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy6,839$0.72$4.90K136,205
Jan 18, 2023Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy6,783$0.74$5.00K129,366
Dec 19, 2022Minai-Azary Jennifer Lynnofficer Chief Financial OfficerP-PurchaseBuy25,000$0.74$18.50K40,000
Dec 19, 2022Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy20,000$0.74$14.80K122,583
Dec 12, 2022Levit Alex C.officer Chief Legal Officer, Corp. SecP-PurchaseBuy6,000$0.85$5.09K9,000
Aug 22, 2022Lehr Martin A.officer Chief Executive OfficerP-PurchaseBuy13,000$1.85$24.06K102,583

The last insider buy of CNTX was made by Lehr Martin A. on Feb 21 2023, buying 5,823 shares at $0.84 per share (worth $4.90K).

Context Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 20243--
Q2 20234--
Q1 20239--
Q4 20223--
Q3 20224--
Q2 20227--
Q1 20225--
Q4 2021152268.18%
Q4 2020---

3 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Context Therapeutics's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q2 2023---
Q1 20236--
Q4 20223--
Q3 20223--
Q2 2022---
Q1 2022---
Q4 20214--
Q4 2020---

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Context Therapeutics's stocks.

Context Therapeutics Peer Ownership


TickerCompany
ZURAZura Bio Limited
GRCLGracell Biotechnologies Inc.
TERNTerns Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
SPROSpero Therapeutics, Inc.
NXTCNextCure, Inc.
VECTVectivBio Holding AG
INABIN8bio, Inc.
XFORX4 Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
WVEWave Life Sciences Ltd.
DAWNDay One Biopharmaceuticals, Inc.
ANNXAnnexon, Inc.
AMLXAmylyx Pharmaceuticals, Inc.
CTMXCytomX Therapeutics, Inc.
BOLTBolt Biotherapeutics, Inc.
NLTXNeurogene Inc.
ASMBAssembly Biosciences, Inc.
CHRSCoherus BioSciences, Inc.

CNTX Ownership FAQ


Context Therapeutics is owned by institutional shareholders (24.65%), insiders (2.78%), and public (72.57%). The largest institutional shareholder of Context Therapeutics is OPALEYE MANAGEMENT INC. (6.94% of total shares) and the top mutual fund owner is BRIDGEWAY FUNDS INC (0.04% of total shares).

Context Therapeutics's major institutional shareholders are OPALEYE MANAGEMENT INC., ALLY BRIDGE GROUP (NY) LLC, VANGUARD GROUP INC, AFFINITY ASSET ADVISORS, LLC, and UBS OCONNOR LLC. The top five shareholders own together 19.15% of the company's share outstanding.

As of Mar 2024, there are 25 institutional shareholders of Context Therapeutics.

OPALEYE MANAGEMENT INC owns 1.11M shares of Context Therapeutics, representing 6.94% of the company's total shares outstanding, valued at $1.53M (as of Mar 2024).

As of Mar 2024, ALLY BRIDGE GROUP (NY) LLC holds 725.95K shares of Context Therapeutics (CNTX), compromising 4.55% of the company, valued at $1M.

VANGUARD GROUP INC is the third largest holder of Context Therapeutics. The company owns 598.3K of the company's shares outstanding (worth $825.66K).